Cephalon Actiq Extensions Start In 2005, Provigil Isomer On Market In 2006
Executive Summary
Cephalon's life-cycle management strategy for the breakthrough cancer pain lozengeActiq includes a sugar-free and fast-acting dosage form
You may also be interested in...
Cephalon Provigil Focus: Studying ADHD In Children, Filing Shift Work sNDA
Cephalon plans to meet with FDA to discuss clinical requirements for a Provigil attention deficit hyperactivity disorder indication following positive results from a Phase II pediatric study, CEO Frank Baldino, PhD, said
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials